Vaginal fungi infections is identified by various symptoms such as swelling around the vagina, burning sensation during urination or sex, whitish-gray and clumpy vaginal discharge, and many others. Vaginal yeast infection is also known as candidiasis. A healthy vagina comprises bacteria and few yeast cells, but when the balance of bacteria and yeast changes, the yeast cells can multiply, which further leads to intense itching, swelling, and irritation.
The global vaginal fungi infections treatment market is estimated to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
Figure 1. Global Vaginal Fungi Infections Treatment Market Share (US$ Mn), by Region, 2020
The increasing product launches is expected to propel growth of the global vaginal fungi infections treatment market
Major players in the market are focused on product launches in the market, which is expected to boost the market growth over the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories Ltd. launched Nystatin and Triamcinolone Acetonide Cream, USP, approved by the U.S. Food & Drug Administration (U.S. FDA).in the U.S. Nystatin and Triamcinolone Acetonide Cream, USP are the generic equivalent of Nystatin and Triamcinolone Acetonide Cream, USP 100,000 units/g- 0.1% manufactured by Taro Pharmaceuticals USA Inc. and these are used to treat fungal or yeast infections of the skin.
Moreover, increasing inorganics strategies such as business expansion adopted by the market players are expected to propel growth of the global vaginal fungi infections treatment market during the forecast period. For instance, in June 2016, Bausch Health Companies Inc. (previously known as Valeant Pharmaceuticals International, Inc.) announced that its subsidiary Valeant Canada is expanding its manufacturing and export capacity in Canada.
However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Pure Essence, a dietary supplement company offers Candex, a mixture of potent enzymes, which break down the substances that make up the cell walls of Candida yeast.
Figure 2. Global Vaginal Fungi Infections Treatment Market Share (%), by Drug Type, 2020
Increasing opioid abuse in North America is expected to boost the market growth
North America is expected to hold dominant position in the global vaginal fungi infections treatment market, owing to burden of recurrent vulvovaginal candidiasis in this region. For instance, according to The Lancet, an article published in August 2018, reports that in the U.S. there were 3,775 and 3,897 base case prevalence per 100,000 females in the U.S. and Canada respectively.
Moreover, increasing acquisitions by key players in the region is expected to drive the market growth during the forecast period. For instance, in February 2019, Aurobindo Pharma Limited acquired commercial operations and certain supporting infrastructure of Apotex Inc. in five European countries.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2019 | Market Size in 2020: | US$ 987.2 Mn |
Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: | 5.3% | 2027 Value Projection: | US$ 1,420.1 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Vaginal Fungi Infections Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment drugs market during the forecast period.
However, the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment market during the forecast period. According to the Journal of Clinical Orthopedics and trauma, in May 2020, the coronavirus affects bones and joints of affected patients. As a result, several orthopedic doctors have been deployed for monitoring patients suffering from coronavirus infection. In order to treat such patients, there has been an increase in the manufacture of drugs and research and development.
Key Players
Major players operating in the global vaginal fungi infections treatment market include Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.
A vaginal yeast infection is a fungal infection that causes irritation, discharge, and intense itchiness of the vagina and the vulva — the tissues at the vaginal opening. Vaginal fungi infection is also known as vaginal yeast infection, vulvovaginal candidiasis, candidal vaginitis or vaginal candidiasis, and it the second most common type of vaginal infection in the U.S., according the Centers for Disease Control and Prevention.
Market Dynamics
Rising incidence of vaginal fungi infections are driving vaginal fungi infections treatment market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2018, around 1.4 million outpatient visits occur for vaginal candidiasis every year in the U.S. Moreover, according to an article published in Multidisciplinary Digital Publishing Institute (MDPI) in February 2020, Vulvovaginal candidiasis (VVC) is the most prevalent human candidal infection and nearly 75% women across the globe are affected by it least once in their lifetime. Furthermore, according to the same source, around 8% women across the globe suffer from Recurrent Vulvovaginal Candidiasis (RVVC).
However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Nutrablast, a dedicated company in the dietary supplement and personal care offers Tea Tree Suppositories for vaginal fungi infections treatment. The product is natural tea tree oil to provide a balanced vaginal environment.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients